SCHEMBL19208522

SCHEMBL19208522

CC(C)(C)OC(=O)Cn1nc(C(N)=O)c2ccc(OCC#N)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 1/20 0.39
▸ SLC2A1 P11166 1/20 0.37
▸ PSEN1 P49768 2/20 0.37
▸ PSEN2 P49810 2/20 0.37
▸ APH1B Q8WW43 2/20 0.37
▸ NCSTN Q92542 2/20 0.37
▸ APH1A Q96BI3 2/20 0.37
▸ PSENEN Q9NZ42 2/20 0.37
▸ KDM4E B2RXH2 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ ALDH2 P05091 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ SCN9A Q15858 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24920125 0.90 DYRK1A (0.39) SLC2A1PSEN1PSEN2APH1BNCSTN
SCHEMBL29781770 0.86 SLC2A1 (0.40) SLC2A1PSEN1PSEN2APH1BNCSTN
SCHEMBL19208780 0.86 SLC2A1 (0.40) SLC2A1PSEN1PSEN2APH1BNCSTN
SCHEMBL19236963 0.85 PSEN1 (0.42) SLC2A1PSEN1PSEN2APH1BNCSTN
SCHEMBL17026536 0.82 CFD (0.40) KDM4EALDH1A1CFD
SCHEMBL15540534 0.81 CFD (0.45) MAPTGAACFD
SCHEMBL29781573 0.78 CFD (0.46) CFD
SCHEMBL19208651 0.78 CFD (0.46) CFD
SCHEMBL12479194 0.78 CFD (0.47) KDM4EALDH1A1HPGDSMN1; SMN2CFD
SCHEMBL12481029 0.75 CFD (0.49) CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 — — US disclosed
EP-3925956-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2024-04-10 — — EP disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 — — US disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 — — US disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 — — US disclosed
US-11559515-B2 Indole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2023-01-24 — — US disclosed
CN-115490751-A Factor D inhibitors 拜奥克里斯特制药公司 2022-12-20 — — CN disclosed
CN-109121414-B Benzopyrazole compounds and analogs thereof 拜奥克里斯特制药公司 2022-07-05 — — CN disclosed
EP-3411411-B3 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2022-01-26 — — EP disclosed
EP-3925956-A1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BioCryst Pharmaceuticals, Inc. (US) 2021-12-22 — — EP disclosed
EP-3411411-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2021-05-19 — — EP disclosed
US-10849883-B2 Benzopyrazole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2020-12-01 — — US disclosed
US-10849883-B2 Benzopyrazole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2020-12-01 — — US disclosed
US-20190142802-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2019-05-16 — — US disclosed
US-20190142802-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2019-05-16 — — US disclosed
EP-3411411-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF Biocryst Pharmaceuticals, Inc. (US) 2018-12-12 — — EP disclosed
WO-2017136395-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2017-08-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof C5, DPYD, C9 GPR119 2722/4885SLC2A1 3750/4885PSEN1 2379/4885
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF C9, C5, C1QBP GPR119 1580/4885SLC2A1 3932/4885PSEN1 2331/4885
US-11559515-B2 Indole compounds and analogues thereof C5, IDO1, IDO2 GPR119 189/4885SLC2A1 2428/4885PSEN1 3071/4885
US-10849883-B2 Benzopyrazole compounds and analogues thereof C9, C5, C1QBP GPR119 1580/4885SLC2A1 3932/4885PSEN1 2331/4885
US-20190142802-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF C9, C5, C1QBP GPR119 1580/4885SLC2A1 3932/4885PSEN1 2331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback